Advertisement

U.S. Markets closed

S&P Futures
5,962.75
+4.50(+0.08%)
Dow Futures
43,978.00
+77.00(+0.18%)
Nasdaq Futures
20,910.00
+16.00(+0.08%)
Russell 2000 Futures
2,409.30
+3.50(+0.15%)
Crude Oil
72.15
+0.46(+0.64%)
Gold
2,664.50
-11.80(-0.44%)

ZyVersa Therapeutics, Inc. (ZVSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

1.5400

-1.0000

(-39.37%)

At close: 04:00PM EST

1.5000

-0.04

(-2.60%)

After hours:

07:44PM EST

Trade prices are not sourced from all markets

All

GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells.Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.The published data showed that inflammasome NLRP3 inhibition was protective of pancreatic islet beta cells, restoring their function and improving metabolic status in an obesity DIO mo
GlobeNewswire
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders.With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight loss. One study showed that immediately after weight loss fat breakdown releases fatty acids triggering an increase in adipose tissue (AT) proinflammatory macrophages and inflammation. Over time, there